Overview

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-06-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect and safety of 608 in patients with AS.
Phase:
PHASE2
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
Adalimumab